BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005;53:247-56. [PMID: 16360548 DOI: 10.1016/j.diagmicrobio.2005.10.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Flamm RK, Sader HS, Castanheira M, Jones RN. The application of in vitro surveillance data for antibacterial dose selection. Current Opinion in Pharmacology 2017;36:130-8. [DOI: 10.1016/j.coph.2017.10.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Koulenti D, Rello J. Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy 2006;7:1555-69. [DOI: 10.1517/14656566.7.12.1555] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
3 Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother 2008;62:369-75. [PMID: 18445575 DOI: 10.1093/jac/dkn184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang Q, Wang Z, Zhang F, Zhao C, Yang B, Sun Z, Mei Y, Zhao F, Liao K, Guo D, Xu X, Sun H, Hu Z, Chu Y, Li Y, Ji P, Wang H. Long-Term Continuous Antimicrobial Resistance Surveillance Among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS). Infect Drug Resist 2020;13:2617-29. [PMID: 32801799 DOI: 10.2147/IDR.S253104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010;10:72. [PMID: 20298555 DOI: 10.1186/1471-2334-10-72] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
6 Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagnostic Microbiology and Infectious Disease 2008;60:421-7. [DOI: 10.1016/j.diagmicrobio.2007.10.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
7 Rempel OR, Laupland KB. Surveillance for antimicrobial resistant organisms: potential sources and magnitude of bias. Epidemiol Infect 2009;137:1665-73. [PMID: 19493372 DOI: 10.1017/S0950268809990100] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
8 Kong L, Tang Y, Zhang X, Lu G, Yu M, Shi Q, Wu X. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation. Ann Pharmacother 2017;51:970-5. [PMID: 28677407 DOI: 10.1177/1060028017719715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Aybey AD, Aksit F, Oz Y, Kiremitci A, Durmaz G. Evaluation of an automated system for the detection of carbapenem resistant Acinetobacter baumannii and assessment of metallo-β-lactamase production using two different phenotyping methods. Journal of Microbiological Methods 2011;86:121-3. [DOI: 10.1016/j.mimet.2011.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Masterton RG. The new treatment paradigm and the role of carbapenems. International Journal of Antimicrobial Agents 2009;33:105.e1-8. [DOI: 10.1016/j.ijantimicag.2008.07.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
11 Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30:657-68. [PMID: 17696578 DOI: 10.2165/00002018-200730080-00002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
12 Sahly H, Navon-Venezia S, Roesler L, Hay A, Carmeli Y, Podschun R, Hennequin C, Forestier C, Ofek I. Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52:3029-34. [PMID: 18573929 DOI: 10.1128/AAC.00010-08] [Cited by in Crossref: 53] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
13 Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A, Spanu T, Pantosti A, Monaco M, Rezza G, Cassone A, Garaci E. Bacterial Isolates from Severe Infections and Their Antibiotic Susceptibility Patterns in Italy: a Nationwide Study in the Hospital Setting. Journal of Chemotherapy 2013;18:589-602. [DOI: 10.1179/joc.2006.18.6.589] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
14 Wen Z, Fan S, Du C, Yin T, Zhou B, Peng Z, Xie Y, Zhang W, Chen Y, Xiao J, Chen X. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther 2017;42:221-7. [DOI: 10.1111/jcpt.12501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
15 Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68:803-38. [PMID: 18416587 DOI: 10.2165/00003495-200868060-00006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
16 Gharrah MM, Mostafa El-Mahdy A, Barwa RF. Association between Virulence Factors and Extended Spectrum Beta-Lactamase Producing Klebsiella pneumoniae Compared to Nonproducing Isolates. Interdiscip Perspect Infect Dis 2017;2017:7279830. [PMID: 28684959 DOI: 10.1155/2017/7279830] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
17 Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med. 2009;24:230-241. [PMID: 19617229 DOI: 10.1177/0885066609335660] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
18 Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9:245-255. [PMID: 19324297 DOI: 10.1016/s1473-3099(09)70055-6] [Cited by in Crossref: 132] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
19 Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res 2011;3:106-10. [PMID: 21811540 DOI: 10.4021/jocmr551w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
20 Koulenti D, Rello J. Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med 2006;12:198-204. [PMID: 16582675 DOI: 10.1097/01.mcp.0000219269.73180.5d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
21 Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z, Chu Y, Hu Z, Huang X. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003–2008. International Journal of Antimicrobial Agents 2010;35:227-34. [DOI: 10.1016/j.ijantimicag.2009.11.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
22 Korten V, Ulusoy S, Zarakolu P, Mete B. Antibiotic resistance surveillance over a 4-year period (2000–2003) in Turkey: results of the MYSTIC Program. Diagnostic Microbiology and Infectious Disease 2007;59:453-7. [DOI: 10.1016/j.diagmicrobio.2007.06.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
23 Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis 2007;59:425-32. [PMID: 17662557 DOI: 10.1016/j.diagmicrobio.2007.05.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
24 Briceño DF, Correa A, Valencia C, Torres JA, Pacheco R, Montealegre MC, Ospina D, Villegas MV, Bacteriana Nosocomial GDR. Actualización de la resistencia a antimicrobianos de bacilos Gram negativos aislados en hospitales de nivel III de Colombia: años 2006, 2007 y 2008. biomedica 2010;30:371. [DOI: 10.7705/biomedica.v30i3.271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Martin CA, Morita K, Ribes JA, Deshpande LM, Sader HS, Castanheira M. IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico. Antimicrob Agents Chemother 2008;52:2289-90. [PMID: 18362195 DOI: 10.1128/AAC.00299-08] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006;56:367-72. [PMID: 17020798 DOI: 10.1016/j.diagmicrobio.2006.07.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 6.2] [Reference Citation Analysis]
27 Kronvall G. Antimicrobial resistance 1979-2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development: ANTIMICROBIAL RESISTANCE 1979-2009 IN STOCKHOLM. APMIS 2010;118:621-39. [DOI: 10.1111/j.1600-0463.2010.02660.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
28 Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int J Infect Dis 2007;11:513-7. [PMID: 17459753 DOI: 10.1016/j.ijid.2007.02.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
29 Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65:414-26. [PMID: 19833471 DOI: 10.1016/j.diagmicrobio.2009.08.020] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 9.8] [Reference Citation Analysis]
30 Kulah C, Aktas E, Comert F, Ozlu N, Akyar I, Ankarali H. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway. BMC Infect Dis 2009;9:30. [PMID: 19291298 DOI: 10.1186/1471-2334-9-30] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
31 Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis. 2008;47 Suppl 1:S21-S31. [PMID: 18713046 DOI: 10.1086/590063] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
32 Masterton RG, Turner PJ. Overview of the Meropenem Yearly Susceptibility Test Information Collection (1997–2004). Diagnostic Microbiology and Infectious Disease 2005;53:245-6. [DOI: 10.1016/j.diagmicrobio.2005.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]